Previous 10 | Next 10 |
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Amylyx To Contact Him Directly To Discuss Their Options If you suffered significant losses in Amylyx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi ...
2023-12-07 10:35:07 ET More on Amylyx Pharma Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector Amylyx Pharmaceuticals: Balancing Growth And Market Challenges (Rating Downgrade) Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2023 Earnings Call Transcript ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis (ALS) from the Phase 2 CENTAUR tria...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has granted stock options and restricted stock units (“RSUs”) to Camille L. Bedrosian, MD, the Company’s newly appointed Chief Medical Officer. The Co...
2023-11-28 07:41:47 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector Amylyx Pharmaceuticals GAAP EPS of $0.30 misses by $0.12, revenue of $102.7M misses by $10.96M For further details see: Amylyx Pharmaceuticals app...
- Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that several abstracts detailing data on AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) and the Company’s investigational antisense oligonucleotide, AMX011...
2023-11-24 00:27:41 ET Summary Amylyx Pharmaceuticals is a biotech company that develops treatments for neurodegenerative diseases, with its product AMX0035 approved by the FDA for ALS therapy. The company's Phase III clinical trials for AMX0035 are expected to yield results in mi...
2023-11-23 23:58:43 ET Summary Amylyx Pharmaceuticals shows impressive revenue growth post-Relyvrio launch, yet faces competition in the ALS treatment market. Financially strong with minimal cash burn and high current ratio; operational challenges like high Relyvrio discontinuatio...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...